
04/18/2025
Employers: It’s Time to Confront the Truth About Your PBM Contract.
The vast majority of employers are unknowingly overpaying for prescription benefits—while Pharmacy Benefit Managers (PBMs) extract massive profits from opaque, misaligned, and self-serving practices.
According to the National Alliance of Healthcare Purchaser Coalitions:
Three PBMs control over 80% of the prescription market—CVS Caremark, Express Scripts, and OptumRx.
These PBMs benefit when drug prices increase, favoring high-rebate drugs over lower-cost generics and biosimilars.
Contracts are filled with gag clauses, spread pricing, and revenue streams PBMs don't disclose.
Many brokers and consultants advising employers receive compensation from PBMs—presenting serious fiduciary concerns under the Consolidated Appropriations Act.
The result? Employers pay more. Employees face rising out-of-pocket costs. And your plan subsidizes the PBM’s bottom line—not better health outcomes.
If you're not actively auditing your PBM, owning your claims data, and demanding full transparency, you are likely violating your fiduciary duty—and leaving significant savings on the table.
Now is the time to act:
Conduct a full PBM contract review.
Eliminate embedded conflicts of interest.
Demand drug-level rebate data and utilization transparency.
Align your pharmacy benefits with your financial and employee health goals.
This isn’t about disruption for its own sake. It’s about restoring value, trust, and accountability to your benefit plan.